Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant olaparib vs placebo in high-risk HER2-negative germline BRCA1/2-mutated primary breast cancer
2024-511096-15-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Olaparib (Lynparza) adjuvant therapy with Placebo adjuvant therapy (2 arms). Primary endpoint: Invasive Disease Free Survival (IDFS). Planned start Mar 2024; status: authorised.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-511096-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511096-15-00.